Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Assets data on record, last reported at $346.8 million in Q1 2026.

  • On a quarterly basis, Assets rose 42.91% to $346.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $346.8 million, a 42.91% increase, with the full-year FY2025 number at $366.3 million, up 40.49% from a year prior.
  • Assets reached $346.8 million in Q1 2026 per FULC's latest filing, down from $366.3 million in the prior quarter.
  • Over the last five years, Assets for FULC hit a ceiling of $366.3 million in Q4 2025 and a floor of $195.2 million in Q2 2022.
  • A 5-year average of $265.5 million and a median of $257.7 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: surged 53.83% in 2023, then decreased 27.57% in 2024.
  • Tracing FULC's Assets over 5 years: stood at $226.7 million in 2022, then rose by 13.68% to $257.7 million in 2023, then grew by 1.17% to $260.7 million in 2024, then soared by 40.49% to $366.3 million in 2025, then dropped by 5.33% to $346.8 million in 2026.
  • Business Quant data shows Assets for FULC at $346.8 million in Q1 2026, $366.3 million in Q4 2025, and $214.9 million in Q3 2025.